Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JH021 in Advanced Solid Tumors
NCT07582822Phase 1Not yet recruiting
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JH021 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC). Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose at 12 months and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
JH021
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07582822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582822.